- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03547063
Responses to Appetite and Taste in the Brain Circuits That Control Eating Behaviour (TASTER)
January 15, 2021 updated by: University College, London
Responses to Appetite and Taste in the Brain Circuits That Control Eating Behaviour: An fMRI Study Evaluating Brain Structure, Connectivity and Responses to Taste Across Different Body Weight Categories and in Response to Weight Loss
The aim of this study is to gain insight into brain structure and the neural networks that control taste and eating behaviour in patients with severe obesity undergoing a primary sleeve gastrectomy (SG) or a lifestyle intervention for weight loss compared with normal weight individuals, using functional magnetic resonance imaging (fMRI).
Study Overview
Status
Suspended
Conditions
Detailed Description
This is an observational study aiming to gain insight into brain structure and the neural networks that control taste and eating behaviour in patients with severe obesity undergoing a primary sleeve gastrectomy (SG) or a lifestyle intervention for weight loss compared with normal weight individuals using functional magnetic resonance imaging (fMRI).
Drops of liquid foods and a control solution will be delivered to the participants' mouth during fMRI scanning.
Body weight, gut hormones from serial blood samples, appetite scores and taste will be assessed at each study visit.
Study Type
Observational
Enrollment (Anticipated)
75
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
London, United Kingdom, NW1 2BU
- University College London Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Participant groups:
Participants with severe obesity
- SG: 25 participants, male and female, aged 18-50 years, body mass index (BMI) 35-50 kg/m2, due to undergo primary SG.
- Lifestyle intervention: 25 participants, male and female, aged 18-50 years, BMI 35-50 kg/m2.
- Participants with normal weight: 25 participants, aged 18-50 years BMI 18.5-24.9 kg/m2, age and gender matched to group with severe obesity.
Description
Inclusion Criteria:
- Female and male adults aged 18-50 years.
- Right-handed.
- No MRI contra-indications.
- Weight stable at time of recruitment, defined as less than 5% variation in body weight over the preceding 3 months.
- Proficient in written and spoken English.
- Able to comply with study protocol.
- Willing and able to provide written informed consent.
- Participants must be registered with a general practitioner (GP).
- Willing for their treating consultant or their GP and the study team to be informed in the event of an incidental abnormal finding being detected by the investigations or assessments that form part of this study.
- Able to lie flat for 1 hour.
Group-specific inclusion criteria:
SG group:
- BMI of 35-50 kg/m2
- Planned to undergo primary SG surgery and fulfilling eligibility criteria for bariatric surgery.
Lifestyle intervention group:
- BMI of 35-50 kg/m2
- Willing to undergo a lifestyle intervention programme with a view to achieving approximately 10% weight loss.
Normal weight group:
- BMI 18.5-24.9 kg/m2
Exclusion Criteria:
- Body weight greater than 130kg (due to weight limit of MRI Scanner).
- Contraindications specific to MRI scanning: metallic implants (cardiac pacemakers, aneurysm clips, permanent eye lining, cochlear implants or anyone who has been exposed to metallic flakes or splinters).
- Type 1 and type 2 diabetes (in view of altered circulated gut hormone profiles and gustatory function).
- Menopause (in view of findings that the menopause affects gustatory function).
- Smoking (in view of the fact that smoking affects salivary gut hormones and gustatory function).
- Vitamin B12 or zinc deficiency (in view of deficiencies affecting gustatory function).
- Untreated severe depression.
- Eating disorders including bulimia and self-induced vomiting.
- Neurological or psychiatric conditions.
- Acute illness or chronic conditions that may impact upon gustatory and olfactory function.
- Acute illness or chronic conditions that may impact upon post-operative weight loss.
- Known or suspected history of HIV, Hepatitis B or C or other blood-borne diseases (in view of safety regulations regarding exposure to blood products)
- Pregnancy or lactation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
|---|
|
Sleeve Gastrectomy (SG)
25 participants, male and female, aged 18-50 years, body mass index (BMI) 35-50 kg/m2, due to undergo primary SG
|
|
Lifestyle Intervention
25 participants, male and female, aged 18-50 years, BMI 35-50 kg/m2
|
|
Normal Weight
25 participants, aged 18-50 years BMI 18.5-24.9
kg/m2, age and gender matched to group with severe obesity
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
BOLD signal change after SG
Time Frame: approximately 6 weeks
|
To determine the effect of SG, at 10% weight loss, upon whole-brain neural response to taste, in the fed and fasted state, detected through blood-oxygen-level dependent (BOLD) signal, in patients with severe obesity.
|
approximately 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
BOLD signal change after lifestyle intervention
Time Frame: average of 12 weeks
|
The effect of 10% weight loss in patients with severe obesity induced by a lifestyle intervention on BOLD signal to taste in the fed and fasted state and compared to SG.
|
average of 12 weeks
|
|
BOLD signal in response to taste in severe obesity compared to normal weight
Time Frame: baseline
|
Brain responses, as BOLD signal, to taste in the fed and fasted state in severe obesity compared to normal weight
|
baseline
|
|
BOLD signal change post-SG
Time Frame: 6 months
|
Whole brain neural response in BOLD signal to taste, in the fed and fasted state, 6 months following SG versus normal weight
|
6 months
|
|
Correlation of taste responses and gut hormones
Time Frame: baseline
|
The relationship between the neural correlates of taste and levels of circulating gut hormones in severe obesity compared to normal weight
|
baseline
|
|
Correlation of taste responses and gut hormones
Time Frame: approximately 6 weeks for SG group and approximately 12 weeks for lifestyle intervention group
|
The relationship between the neural correlates of taste and levels of circulating gut hormones after 10% weight loss by SG compared to lifestyle intervention
|
approximately 6 weeks for SG group and approximately 12 weeks for lifestyle intervention group
|
|
Correlation of taste responses and gut hormones
Time Frame: 6 months post-SG compared to baseline
|
The relationship between the neural correlates of taste and circulating gut hormone levels
|
6 months post-SG compared to baseline
|
|
Correlation of taste responses and gut hormones
Time Frame: 6 months
|
The relationship between the neural correlates of taste and levels of circulating gut hormones post-SG compared to normal weight
|
6 months
|
|
Brain structure
Time Frame: Baseline
|
Comparison of brain structure in severe obesity and normal weight
|
Baseline
|
|
Brain structure 6 months following SG
Time Frame: 6 months
|
Comparison of brain structure 6 months following SG to baseline
|
6 months
|
|
Brain structure after 10% weight loss
Time Frame: approximately 6 weeks for SG group and approximately 12 weeks for lifestyle intervention group
|
Comparison of brain structure following 10% weight loss induced by SG versus lifestyle intervention
|
approximately 6 weeks for SG group and approximately 12 weeks for lifestyle intervention group
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Rachel L Batterham, PhD FRCP, UCL
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Makaronidis JM, Neilson S, Cheung WH, Tymoszuk U, Pucci A, Finer N, Doyle J, Hashemi M, Elkalaawy M, Adamo M, Jenkinson A, Batterham RL. Reported appetite, taste and smell changes following Roux-en-Y gastric bypass and sleeve gastrectomy: Effect of gender, type 2 diabetes and relationship to post-operative weight loss. Appetite. 2016 Dec 1;107:93-105. doi: 10.1016/j.appet.2016.07.029. Epub 2016 Jul 22.
- Batterham RL, ffytche DH, Rosenthal JM, Zelaya FO, Barker GJ, Withers DJ, Williams SC. PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature. 2007 Nov 1;450(7166):106-9. doi: 10.1038/nature06212. Epub 2007 Oct 14.
- Neseliler S, Han JE, Dagher A. The Use of Functional Magnetic Resonance Imaging in the Study of Appetite and Obesity. In: Harris RBS, editor. Appetite and Food Intake: Central Control. 2nd edition. Boca Raton (FL): CRC Press/Taylor & Francis; 2017. Chapter 6. Available from http://www.ncbi.nlm.nih.gov/books/NBK453146/
- Zhang Y, Ji G, Xu M, Cai W, Zhu Q, Qian L, Zhang YE, Yuan K, Liu J, Li Q, Cui G, Wang H, Zhao Q, Wu K, Fan D, Gold MS, Tian J, Tomasi D, Liu Y, Nie Y, Wang GJ. Recovery of brain structural abnormalities in morbidly obese patients after bariatric surgery. Int J Obes (Lond). 2016 Oct;40(10):1558-1565. doi: 10.1038/ijo.2016.98. Epub 2016 May 20.
- Goldstone AP, Miras AD, Scholtz S, Jackson S, Neff KJ, Penicaud L, Geoghegan J, Chhina N, Durighel G, Bell JD, Meillon S, le Roux CW. Link Between Increased Satiety Gut Hormones and Reduced Food Reward After Gastric Bypass Surgery for Obesity. J Clin Endocrinol Metab. 2016 Feb;101(2):599-609. doi: 10.1210/jc.2015-2665. Epub 2015 Nov 18.
- Faulconbridge LF, Ruparel K, Loughead J, Allison KC, Hesson LA, Fabricatore AN, Rochette A, Ritter S, Hopson RD, Sarwer DB, Williams NN, Geliebter A, Gur RC, Wadden TA. Changes in neural responsivity to highly palatable foods following roux-en-Y gastric bypass, sleeve gastrectomy, or weight stability: An fMRI study. Obesity (Silver Spring). 2016 May;24(5):1054-60. doi: 10.1002/oby.21464.
- Karra E, O'Daly OG, Choudhury AI, Yousseif A, Millership S, Neary MT, Scott WR, Chandarana K, Manning S, Hess ME, Iwakura H, Akamizu T, Millet Q, Gelegen C, Drew ME, Rahman S, Emmanuel JJ, Williams SC, Ruther UU, Bruning JC, Withers DJ, Zelaya FO, Batterham RL. A link between FTO, ghrelin, and impaired brain food-cue responsivity. J Clin Invest. 2013 Aug;123(8):3539-51. doi: 10.1172/JCI44403. Epub 2013 Jul 15.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 18, 2018
Primary Completion (Anticipated)
December 1, 2021
Study Completion (Anticipated)
December 1, 2022
Study Registration Dates
First Submitted
May 11, 2018
First Submitted That Met QC Criteria
May 23, 2018
First Posted (Actual)
June 6, 2018
Study Record Updates
Last Update Posted (Actual)
January 20, 2021
Last Update Submitted That Met QC Criteria
January 15, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18/0233
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical ConditionsUnited States
-
Central Hospital, Nancy, FranceNot yet recruiting
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsCompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation TechniquesUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium